Alvogen Continues IP Fight Over Cancer Drug Imbruvica

By Piper Hudspeth Blackburn · October 7, 2022, 8:14 PM EDT

In a rematch over the leukemia medication Imbruvica, AbbVie's Pharmacyclics LLC and Johnson & Johnson's Janssen Biotech urged the Federal Circuit Friday to uphold a lower court ruling that their four...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Pharmacyclics LLC et al v. Alvogen Pine Brook LLC et al

Case Number

1:19-cv-00434

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

March 01, 2019

Case Title

Pharmacyclics LLC v. Alvogen, Inc.

Case Number

21-2270

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

August 31, 2021

Recent Articles By Piper

May 15, 2023
Anti-Vaccine Antitrust Suit Moved From Texas To NY
May 10, 2023
UnitedHealth Unit Cites Latest DOJ 'No-Poach' Loss To Exit Suit
May 05, 2023
3rd Circ. Upholds Class Cert. Denial In Niaspan MDL
May 03, 2023
Panel Affirms Ga. Hospital's Need For New Surgery Center
May 02, 2023
Ga. Justices To Review Fight Over Hospital Change
April 25, 2023
FTC Pauses Illumina-Grail Order Amid 5th Circ. Appeal
April 24, 2023
Motorola Gets Brain Cancer Cellphone Suit Slashed
April 14, 2023
9th Circ. Upholds Health Care Co.'s Win In TCPA Suit
March 29, 2023
McKesson Beats Oncology Kickback Whistleblower Suit
March 28, 2023
Hospital Chain Seeks Sanctions Over Patients' Antitrust Case

Alvogen Continues IP Fight Over Cancer Drug Imbruvica

Related Sections

Case Information

Case Title

Case Number

Court

Nature of Suit

Date Filed

Case Title

Case Number

Court

Nature of Suit

Date Filed

Recent Articles By Piper